Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Filippo Luca Fimognari is active.

Publication


Featured researches published by Filippo Luca Fimognari.


Internal and Emergency Medicine | 2008

Portal vein thrombosis in liver cirrhosis.

Filippo Luca Fimognari; Francesco Violi

Portal vein thrombosis (PVT) is observed in 10–20% of patients with liver cirrhosis, which is responsible for 20% of all PVT cases. The main pathogenic factor of PVT in cirrhosis is the obstacle to portal flow, but acquired and inherited clotting abnormalities may play a role. The formation of collateral veins allows many patients to remain asymptomatic and prevents the onset of clinical complications also in patients with totally occlusive PVT. Gastrointestinal bleeding, thrombosis of superior mesenteric vein and refractory ascites are typical manifestations of PVT. Instrumental diagnosis can be obtained by colour-doppler ultrasonography. Future studies should verify whether asymptomatic PVT worsens liver failure, or if its life-threatening complications reduce survival in patients with cirrhosis. Moreover, randomized controlled trials should clarify the potential effectiveness of anticoagulant therapy in the treatment of PVT.


Angiology | 2008

Endothelial Dysfunction in Chronic Obstructive Pulmonary Disease

Leo Moro; Claudio Pedone; Simone Scarlata; Vincenzo Malafarina; Filippo Luca Fimognari; Raffaele Antonelli-Incalzi

Background: Cardiovascular diseases are prevalent in people with chronic obstructive pulmonary disease (COPD). We hypothesized that endothelial dysfunction could be a marker of the proatherogen status in COPD. Methods and results: We measured endothelial dysfunction by flow-mediated dilation (FMD) and after sublingual administration of nitroglycerin (nitrate-mediated dilation: NMD) in 44 COPD patients and 48 controls. Compared with controls COPD patients had worse mean FMD (5.4% vs 8.2%, P < .001) and NMD (12.0% vs 13.9%, P = .007). FMD was inversely related to FEV1/VC ratio (r = −0.327, P = .030). The negative association between COPD and FMD was confirmed after correction for potential confounders in a multiple linear regression model (β = −0.019, P = .002). In the same model NMD (β = 0.396, P < .001) was positively associated with FMD. Conclusions: Endothelial-dependent and, to a lesser extent, endothelial-independent dilations are significantly impaired in COPD, and the impairment is proportional to the severity of bronchial obstruction.


Diabetes Care | 2006

Metformin-Induced Pancreatitis: A possible adverse drug effect during acute renal failure

Filippo Luca Fimognari; Andrea Corsonello; Ruggero Pastorell; Raffaele Antonelli-Incalzi

About 2% of episodes of acute pancreatitis are caused by drugs (1). Phenformin was repeatedly associated with acute pancreatitis (1), but only two case reports highlighted a possible causative role for metformin (2,3). In one case, acute pancreatitis occurred for the coexistence of correct metformin treatment and acute renal failure (2); in the other, metformin overdose was deemed responsible (3). A 61-year-old woman with diabetes and hypercholesterolemia presented after 5 days of vomiting, followed by oliguria and epigastric pain. At home, the therapy of 3 …


Nutrition Metabolism and Cardiovascular Diseases | 2009

Hyperhomocysteinaemia and poor vitamin B status in chronic obstructive pulmonary disease

Filippo Luca Fimognari; Lorenzo Loffredo; Francesca Sampietro; Ruggero Pastorelli; M. Monaldo; Francesco Violi; A. D'Angelo

BACKGROUND AND AIMS Patients with chronic obstructive pulmonary disease (COPD) are at increased atherothrombotic risk. Preliminary findings have suggested that COPD patients may have increased plasma total homocysteine (tHcy), a cardiovascular risk factor often caused by a poor B vitamin status, but plasma levels of such vitamins were not measured. The aim of this study was to investigate hyperhomocysteinaemia in COPD and to determine whether it may be secondary to poor plasma concentrations of B vitamins. METHODS AND RESULTS We performed a case-control, cross-sectional study of 42 patients with COPD and 29 control subjects. Folate, vitamin B12, vitamin B6, tHcy, renal function, C-reactive protein, blood gases and lipids were measured in patients and controls. COPD patients had higher plasma tHcy (median: 13.9mumol/l, interquantile range [IQR]: 12.1-18.5 versus 11.5, IQR: 10.1-14, p=0.002) and lower circulating folate (median: 2.5ng/ml, IQR: 1.2-3.3 versus 2.8, IQR: 2.1-4 of controls, p=0.03) than controls had. Compared to the control group, COPD was associated with higher tHcy concentrations also after adjusting for smoking, heart failure, renal function and C-reactive protein with logistic regression analysis (OR 1.36, 95% CI 1.06-1.72, p=0.01). In the COPD group, low levels of folate (beta=-0.27, p=0.02) and vitamin B12 (beta=-0.24, p=0.04), and hypertriglyceridaemia (beta=0.580, p<0.0001) were independent predictors of the presence of high tHcy concentrations in a multiple linear regression model (adjusted R(2)=0.522). CONCLUSION COPD patients have a poor B vitamin status and, as a consequence, increased tHcy. These abnormalities may contribute to the COPD-related atherothrombotic risk.


Geriatrics & Gerontology International | 2013

Lung function changes in older people with metabolic syndrome and diabetes

Simone Scarlata; Filippo Luca Fimognari; Matteo Cesari; Renato Giua; Alessandro Franco; Patrizio Pasqualetti; Ruggero Pastorelli; Raffaele Antonelli-Incalzi

Restrictive lung dysfunction (RLD; defined as reduced forced vital capacity [FVC] in the presence of normal forced expiratory volume in 1 s [FEV1]/FVC ratio) is highly prevalent in the elderly, and is associated with diabetes, metabolic syndrome (MetS) and abdominal obesity. The aim of this study was to assess the relative contribution of diabetes, MetS and abdominal obesity in characterizing RLD in the elderly.


Annals of Pharmacotherapy | 2009

Erlotinib-Induced Hepatitis Complicated by Fatal Lactic Acidosis in an Elderly Man With Lung Cancer

Marco Pellegrinotti; Filippo Luca Fimognari; Alessandro Franco; Lazzaro Repetto; Ruggero Pastorelli

Objective: To report a case of erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly patient with lung adenocarcinoma and diabetes mellitus. Case Summary: A 77-year-old man with stage IIIB lung adenocarcinoma was treated with erlotinib 100 mg/day, an epidermal growth factor receptor inhibitor, after failure of chemotherapy and radiotherapy. The patient also had type 2 diabetes mellitus; metformin therapy had been initiated 5 years before presentation. Twelve days after the start of erlotinib therapy, he developed drug-related acute hepatitis complicated by renal deterioration (aspartate aminotransferase 1400 U/L, alanine aminotransferase 1299 U/L, creatinine 4.4 mg/dL, urea nitrogen 55 mg/dL). Viral causes of hepatitis were excluded and a recent computed tomography scan had ruled out liver metastases. According to the Roussel-Uclaf causality assessment method, the erlotinib-related hepatitis was classified as probable. The patients condition was soon complicated by the onset of lactic acidosis, which caused death 2 hours after admission. Discussion: In this patient, lactic acidosis was promoted by erlotinib-related hepatitis with initial liver failure (decreased lactate clearance), concomitant metformin treatment (increased lactate production), and acute renal deterioration (metformin accumulation). This is the second case of fatal erlotinib-induced liver toxicity in a patient with lung cancer. In the previous case, death occurred after about 11 days and was entirely due to fulminant hepatitis, whereas in our patient, the liver injury only initiated a drug–disease interaction that caused fatal lactic acidosis within a lew hours. Conclusions: Liver function should be carefully monitored during erlotinib treatment, particularly in elderly and frail patients on multiple medications. Further studies are therefore needed for better testing the safety of erlotinib in such people, commonly encountered in the real world, but often excluded from participation in randomized trials of cancer treatment.


The American Journal of the Medical Sciences | 1994

High Plasma Concentrations of Cortisol and Thromboxane B2 in Patients With Depression

Gianfranco Piccirillo; Filippo Luca Fimognari; Vincenzo Infantino; Girolamo Monteleone; Giuseppe Beniamino Fimognari; Domenico Falletti; Vincenzo Marigliano

Modulation of the hypothalamic-pituitary-adrenal axis in major depression is thought to depend on the hypothalamus and other areas of the central nervous system, or both. Hypothalamic over-activity may be responsible for the hypercortisolism observed in 50% of depressed subjects. To investigate the relation between psychosocial factors and cardiovascular disease, morning (8 AM) plasma concentrations of cortisol and thromboxane B2 (the stable metabolite of thromboxane A2, an eicosanoid closely linked to thrombotic disorders) were measured by radioimmunoassay in 32 patients with major depression (DSM III) triggered by psychosocial events and in 9 nondepressed volunteers. The depressed patients were studied in two groups, 16 with cortisol levels under 90 ng/mL and 16 with levels over 90 ng/mL. All the healthy non-depressed subjects had cortisol values over 100 ng/mL. The depressed patients with high cortisol had significantly higher plasma TxB2 concentrations than the other two groups. In addition, plasma cortisol and TxB2 concentrations correlated significantly over the whole group of depressed patients and in the high cortisol subgroup but not in the low-cortisol sub-group or in the nondepressed subjects. These findings appear to support the recently proposed role of the hypothalamic dysfunction associated with affective disorders in the pathogenesis of cardiovascular disease.


Journal of Laboratory and Clinical Medicine | 1996

Associated daily biosynthesis of cortisol and thromboxane A2: A preliminary report

Filippo Luca Fimognari; Gianfranco Piccirillo; Jaime Lama; Patrizia Paganica; Girolamo Monteleone; Walter Gianni; Mauro Cacciafesta; Vincenzo Marigliano

Cortisol is the most important hormone secreted in response to acute and chronic stress. Thromboxane A2 (TxA2) is a potent eicosanoid with vasoconstricting and proaggregatory actions. Our earlier finding of a close correlation between plasma levels of TxB2, the stable metabolite of TxA2, and cortisol in subjects with major depression but without frank hypercortisolism prompted us to investigate a possible association between TxA2 and cortisol production in nondepressed subjects. The 24-hour urinary excretion values of 2,3-dinor-TxB2 (the urinary catabolite of TxA2) and cortisol were measured by radioimmunoassay in 50 subjects divided into three groups matched for age, sex distribution, and body mass index. Group 1 consisted of 19 healthy subjects; group 2 consisted of 15 patients with type IIa hypercholesterolemia, a condition associated with a high atherothrombotic risk, but without history of atherosclerosis or evidence of this disorder documented clinically or in noninvasive diagnostic tests; and group 3 consisted of 16 patients with regional atherosclerosis (8 with cerebrovascular disease, 6 with coronary artery disease, and 2 with peripheral vascular disease). Although the three groups had similar cortisol and 2,3-dinor-TxB2 urinary values, a significant direct correlation emerged between the two catabolites in the whole study sample (r = 0.63; p < 0.0001) and the three groups (r1 = 0.62, p < 0.01; r2 = 0.78, p < 0.0001; r3 = 0.63, p < 0.01). The close association between cortisol and thromboxane A2 biosynthesis thus appears to be a general phenomenon. These findings may be important in interpreting the well-described causative link between stress and atherothrombotic cardiovascular disease.


Geriatrics & Gerontology International | 2014

Acute functional decline before hospitalization in older patients.

Lorenzo Palleschi; Filippo Luca Fimognari; Andrea Pierantozzi; Bernardo Salani; Alberto Marsilii; Stefano Maria Zuccaro; Luigi Di Cioccio; Walter De Alfieri

Acute diseases and related hospitalization are crucial events in the disabling process of elderly individuals. Most of the functional decline occurs in the few days before hospitalization, as a result of acute diseases in vulnerable patients. The aim of the present study was to identify determinants of prehospital components of functional decline.


Digestion | 1997

Scintigraphic Imaging of Hepatic Epithelioid Hemangioendothelioma

Walter Gianni; Giuseppe De Vincentis; Paolo Graziano; Maria lerardi; Filippo Luca Fimognari; M. Banci; Paola Gazzaniga; Mauro Cacciafesta; Ugo Di Tondo; Francesco Scopinaro; Vincenzo Marigliano

The epithelioid hemangioendothelioma of the liver has been recently characterized as a rare tumor with distinctive pathological features affecting young adults. Our report describes a case of histologically confirmed primary epithelioid hemangioendothelioma of the liver, diagnosed by clinical examination as well as radiological (CT/MR) and scintigraphic imaging (labelled red cells/ phytate-SPECT). This case highlights the usefulness of nuclear medicine techniques during the diagnostic of this rare tumor. Further it stresses the possibility of employing an easy and noninvasive method to adequately follow-up those patients who cannot be considered as disease-free even after orthotopic liver transplantation because of the recurrence of the disease in the transplanted liver.

Collaboration


Dive into the Filippo Luca Fimognari's collaboration.

Top Co-Authors

Avatar

Francesco Violi

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Simone Scarlata

Università Campus Bio-Medico

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Leo Moro

Università Campus Bio-Medico

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lorenzo Loffredo

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Claudio Pedone

Università Campus Bio-Medico

View shared research outputs
Researchain Logo
Decentralizing Knowledge